Roche, Zealand and weight loss

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche-Zealand deal is the latest to boost obesity space
Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts weight loss drug stocks. Read more here.
Fierce Pharma5d
Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment
Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...
Medical Device Network on MSN1d
Roche Diagnostics supports UK eye cancer AI initiative
Roche Diagnostics is collaborating with the University of Liverpool to launch the Eye Cancer Artificial Intelligence Digital ...
Investopedia3d
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive ...
Fierce Biotech8d
Roche to house its CVRM research work at Harvard's new research campus
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal ...
Analysts Offer Insights on Healthcare Companies: Knight Therapeutics (OtherKHTRF) and Roche Holding AG (OtherRHHVF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Knight Therapeutics (KHTRF – Research Report) ...
SWI swissinfo.ch8d
Roche builds innovation centre on Harvard campus
Pharmaceutical giant Roche announces opening of an innovation centre at Harvard University's corporate research campus.
The Boston Globe8d
Roche to open innovation center at new Harvard campus in Allston that could employ hundreds
Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...
Little Rock Public Radio1d
Some acne treatments from brands like Walgreens, La Roche-Posay voluntarily recalled
The FDA tested 95 products containing benzoyl peroxide, an ingredient widely used to treat acne that can form benzene as a ...